[{"orgOrder":0,"company":"Leads Biolabs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"LBL-024","moa":"4-1BB\/PDL1","graph1":"Oncology","graph2":"Phase II","graph3":"Leads Biolabs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Leads Biolabs \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Leads Biolabs \/ Undisclosed"},{"orgOrder":0,"company":"Leads Biolabs","sponsor":"Sun Yat-sen University | Mianyang Central Hospital | Xiangyang Central Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"LBL-024","moa":"4-1BB\/PDL1","graph1":"Oncology","graph2":"Phase II","graph3":"Leads Biolabs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Leads Biolabs \/ Sun Yat-sen University | Mianyang Central Hospital | Xiangyang Central Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Leads Biolabs \/ Sun Yat-sen University | Mianyang Central Hospital | Xiangyang Central Hospital"},{"orgOrder":0,"company":"Leads Biolabs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"LBL-024","moa":"4-1BB\/PDL1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Leads Biolabs","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Leads Biolabs \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Leads Biolabs \/ Undisclosed"},{"orgOrder":0,"company":"Leads Biolabs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"LBL-024","moa":"4-1BB\/PDL1","graph1":"Oncology","graph2":"Phase II","graph3":"Leads Biolabs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Leads Biolabs \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Leads Biolabs \/ Undisclosed"},{"orgOrder":0,"company":"Leads Biolabs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Etoposide","moa":"||4-1BB\/PDL1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Leads Biolabs","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Leads Biolabs \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Leads Biolabs \/ Undisclosed"},{"orgOrder":0,"company":"Leads Biolabs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Cisplatin","moa":"||4-1BB\/PDL1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Leads Biolabs","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Leads Biolabs \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Leads Biolabs \/ Undisclosed"},{"orgOrder":0,"company":"Leads Biolabs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"LBL-024","moa":"4-1BB|PDL1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Leads Biolabs","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Leads Biolabs \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Leads Biolabs \/ Undisclosed"},{"orgOrder":0,"company":"Leads Biolabs","sponsor":"Shanghai Zhongshan Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"LBL-024","moa":"4-1BB|PDL1","graph1":"Oncology","graph2":"Phase II","graph3":"Leads Biolabs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Leads Biolabs \/ Shanghai Zhongshan Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Leads Biolabs \/ Shanghai Zhongshan Hospital"},{"orgOrder":0,"company":"Leads Biolabs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"LBL-024","moa":"4-1BB|PDL1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Leads Biolabs","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Leads Biolabs \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Leads Biolabs \/ Undisclosed"},{"orgOrder":0,"company":"Leads Biolabs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"LBL-034","moa":"CD3\/GPRC5D","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Leads Biolabs","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Leads Biolabs \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Leads Biolabs \/ Undisclosed"},{"orgOrder":0,"company":"Leads Biolabs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"LBL-034","moa":"CD3\/GPRC5D","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Leads Biolabs","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Leads Biolabs \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Leads Biolabs \/ Undisclosed"},{"orgOrder":0,"company":"Leads Biolabs","sponsor":"Henan Cancer Hospital | Hunan Cancer Hospital | Shandong Cancer Hospital and Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"LBL-003","moa":"CD33","graph1":"Oncology","graph2":"Phase I","graph3":"Leads Biolabs","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Leads Biolabs \/ Henan Cancer Hospital | Hunan Cancer Hospital | Shandong Cancer Hospital and Institute","highestDevelopmentStatusID":"6","companyTruncated":"Leads Biolabs \/ Henan Cancer Hospital | Hunan Cancer Hospital | Shandong Cancer Hospital and Institute"},{"orgOrder":0,"company":"Leads Biolabs","sponsor":"Chime Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Agreement","leadProduct":"LBL-007","moa":"||LAG3 pathway","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Leads Biolabs","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Leads Biolabs \/ Leads Biolabs","highestDevelopmentStatusID":"7","companyTruncated":"Leads Biolabs \/ Leads Biolabs"},{"orgOrder":0,"company":"Leads Biolabs","sponsor":"BeOne Medicines","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Collaboration","leadProduct":"LBL-007","moa":"||LAG3 pathway","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Leads Biolabs","amount2":0.77000000000000002,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.77000000000000002,"dosageForm":"Infusion","sponsorNew":"Leads Biolabs \/ BeiGene","highestDevelopmentStatusID":"7","companyTruncated":"Leads Biolabs \/ BeiGene"},{"orgOrder":0,"company":"Leads Biolabs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"LBL-007","moa":"LAG3 pathway","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Leads Biolabs","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Leads Biolabs \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Leads Biolabs \/ Undisclosed"},{"orgOrder":0,"company":"Leads Biolabs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"LBL-007","moa":"LAG3 pathway","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Leads Biolabs","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Leads Biolabs \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Leads Biolabs \/ Undisclosed"},{"orgOrder":0,"company":"Leads Biolabs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"LBL-007","moa":"LAG3 pathway","graph1":"Oncology","graph2":"Phase I","graph3":"Leads Biolabs","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Leads Biolabs \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Leads Biolabs \/ Undisclosed"},{"orgOrder":0,"company":"Leads Biolabs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"LBL-033","moa":"MUC16\/CD3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Leads Biolabs","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Leads Biolabs \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Leads Biolabs \/ Undisclosed"},{"orgOrder":0,"company":"Leads Biolabs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"LBL-033","moa":"MUC16\/CD3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Leads Biolabs","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Leads Biolabs \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Leads Biolabs \/ Undisclosed"},{"orgOrder":0,"company":"Leads Biolabs","sponsor":"Shanghai East Hospital | Shandong Cancer Hospital and Institute | Henan Cancer Hospital | Hunan Cancer Hospital | The First Affiliated Hospital of Nanchang University | The First Affiliated Hospital of Bengbu Medical University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"LBL-015","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Leads Biolabs","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Leads Biolabs \/ Shanghai East Hospital | Shandong Cancer Hospital and Institute | Henan Cancer Hospital | Hunan Cancer Hospital | The First Affiliated Hospital of Nanchang University | The First Affiliated Hospital of Bengbu Medical University","highestDevelopmentStatusID":"7","companyTruncated":"Leads Biolabs \/ Shanghai East Hospital | Shandong Cancer Hospital and Institute | Henan Cancer Hospital | Hunan Cancer Hospital | The First Affiliated Hospital of Nanchang University | The First Affiliated Hospital of Bengbu Medical University"},{"orgOrder":0,"company":"Leads Biolabs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"LBL-019","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Leads Biolabs","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Leads Biolabs \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Leads Biolabs \/ Undisclosed"}]
Find Clinical Drug Pipeline Developments & Deals by Leads Biolabs
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target